Lantheus (NASDAQ:LNTH) Updates FY 2024 Earnings Guidance

Lantheus (NASDAQ:LNTH - Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 6.650-6.700 for the period, compared to the consensus earnings per share estimate of 6.660. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion. Lantheus also updated its FY24 guidance to $6.65-6.70 EPS.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Leerink Partners upped their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Thursday, July 11th. Redburn Atlantic started coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective for the company. JMP Securities dropped their target price on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a report on Thursday, August 1st. Truist Financial cut their target price on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. Finally, B. Riley increased their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Lantheus currently has an average rating of "Moderate Buy" and an average price target of $126.00.

Lantheus Stock Down 22.0 %

Lantheus stock traded down $25.30 during mid-day trading on Wednesday, reaching $89.66. The stock had a trading volume of 4,347,404 shares, compared to its average volume of 974,165. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. Lantheus has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The stock's 50-day simple moving average is $108.41 and its 200-day simple moving average is $95.60. The firm has a market capitalization of $6.23 billion, a PE ratio of 15.36 and a beta of 0.51.

Insider Buying and Selling at Lantheus

In related news, Director Gerard Ber sold 15,500 shares of the company's stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Paul Blanchfield sold 2,000 shares of the company's stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the transaction, the president now owns 98,980 shares of the company's stock, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by company insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.